- Home
- DOYU vs NYXH Comparison
DOYU vs NYXH Comparison
Compare DOYU & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOYU
- NYXH
- Stock Information
- Founded
- DOYU 2014
- NYXH 2009
- Country
- DOYU China
- NYXH Belgium
- Employees
- DOYU N/A
- NYXH N/A
- Industry
- DOYU Computer Software: Programming Data Processing
- NYXH Medical/Dental Instruments
- Sector
- DOYU Technology
- NYXH Health Care
- Exchange
- DOYU Nasdaq
- NYXH Nasdaq
- Market Cap
- DOYU 246.3M
- NYXH 231.0M
- IPO Year
- DOYU 2019
- NYXH 2021
- Fundamental
- Price
- DOYU $7.89
- NYXH $5.50
- Analyst Decision
- DOYU Hold
- NYXH Strong Buy
- Analyst Count
- DOYU 1
- NYXH 3
- Target Price
- DOYU $7.00
- NYXH $15.00
- AVG Volume (30 Days)
- DOYU 83.0K
- NYXH 87.7K
- Earning Date
- DOYU 08-18-2025
- NYXH 11-05-2025
- Dividend Yield
- DOYU 243.48%
- NYXH N/A
- EPS Growth
- DOYU N/A
- NYXH N/A
- EPS
- DOYU N/A
- NYXH N/A
- Revenue
- DOYU $586,290,301.00
- NYXH $5,793,306.00
- Revenue This Year
- DOYU N/A
- NYXH $144.57
- Revenue Next Year
- DOYU N/A
- NYXH $244.36
- P/E Ratio
- DOYU N/A
- NYXH N/A
- Revenue Growth
- DOYU N/A
- NYXH 2.94
- 52 Week Low
- DOYU $5.68
- NYXH $5.45
- 52 Week High
- DOYU $16.99
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- DOYU 49.96
- NYXH 31.10
- Support Level
- DOYU $7.69
- NYXH $5.45
- Resistance Level
- DOYU $8.19
- NYXH $6.09
- Average True Range (ATR)
- DOYU 0.44
- NYXH 0.25
- MACD
- DOYU -0.00
- NYXH -0.02
- Stochastic Oscillator
- DOYU 50.00
- NYXH 4.37
About DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.